Adenovirus Anti-Tumour Therapy Patent
Summary
The European Patent Office published patent application EP4158036A1 for an adenovirus-based anti-tumour therapy developed by Medizinische Hochschule Hannover. The invention relates to engineered adenoviruses (IPC C12N 15/861, A61K 35/761) for cancer treatment. The patent is designated for all 31 EPC contracting states including DE, FR, GB, IT, NL, ES, and CH.
What changed
The EPO published patent EP4158036A1 for an adenovirus-based anti-tumour therapy invented by researchers at Medizinische Hochschule Hannover (Germany). The invention covers engineered adenoviruses for cancer treatment with IPC classifications C12N 15/861 and A61K 35/761. Inventors include Kühnell, Wollter, and Kubicka. The patent designates all 31 EPC contracting states.
Healthcare providers, biotech companies, and researchers developing oncolytic virus therapies should review the patent claims for freedom-to-operate considerations. The patent provides exclusive rights in EPO member states including Germany, France, UK, Italy, Netherlands, Spain, Switzerland, and others. No immediate compliance action is required; this is informational for IP strategy and competitive intelligence purposes.
Source document (simplified)
ADENOVIRUS FOR ANTI-TUMOUR THERAPY
Publication EP4158036A1 Kind: A1 Mar 25, 2026
Applicants
Medizinische Hochschule Hannover
Inventors
KÜHNEL, Florian, WOLLER, Norman, KUBICKA, Stefan
IPC Classifications
C12N 15/861 20060101AFI20211203BHEP A61K 35/761 20150101ALI20211203BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Biotech (C12N) publishes new changes.